ArticleExperimental hematology & oncology2017

Extraordinary clinical benefit to sequential treatment with targeted therapy and immunotherapy of a BRAF V600E and PD-L1 positive metastatic lung adenocarcinoma.

Shuyu D Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.